Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Leases (2016 - 2025)

Historic Current Leases for ImmunityBio (IBRX) over the last 10 years, with Q3 2025 value amounting to $7.3 million.

  • ImmunityBio's Current Leases rose 402.39% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 402.39%. This contributed to the annual value of $7.5 million for FY2024, which is 4237.22% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Current Leases is $7.3 million, which was up 402.39% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Current Leases peaked at $7.5 million during Q4 2024, and registered a low of $1.4 million during Q3 2022.
  • Moreover, its 5-year median value for Current Leases was $5.2 million (2021), whereas its average is $4.7 million.
  • Its Current Leases has fluctuated over the past 5 years, first tumbled by 5556.64% in 2022, then skyrocketed by 32621.08% in 2023.
  • ImmunityBio's Current Leases (Quarter) stood at $3.0 million in 2021, then decreased by 11.99% to $2.6 million in 2022, then soared by 97.89% to $5.2 million in 2023, then soared by 42.37% to $7.5 million in 2024, then decreased by 2.01% to $7.3 million in 2025.
  • Its Current Leases was $7.3 million in Q3 2025, compared to $7.4 million in Q2 2025 and $7.5 million in Q1 2025.